Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in PharmacologyOpen Access

Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXiaojian WangXLXinyi LiangCLChenchen Li

Discussion

Loading...

Member takes

Overview

Meta-analysis shows CDK4/6 inhibitors plus endocrine therapy improves progression-free survival and overall survival in HR+/HER2 breast cancer, indicating a potential treatment advantage.

Key Points

  • CDK4/6 inhibitors plus endocrine therapy significantly improve overall survival compared to endocrine therapy alone.
  • The study analyzed data from 12 randomized controlled trials involving 4,957 patients with HR+/HER2-metastatic breast cancer.
  • Progression-free survival was markedly higher in the group receiving CDK4/6 inhibitors plus endocrine therapy.
  • While effective, the combination therapy also resulted in higher severe treatment-related adverse events.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c240deb210217d6479c09bhttps://doi.org/10.3389/fphar.2025.1600892
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis2025
  2. 2Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)2025
  3. 3Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer2025
  4. 4Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment Naivety2025
  5. 5Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis2025